[
    {
        "file_name": "AimmuneTherapeuticsInc_20200205_8-K_EX-10.3_11967170_EX-10.3_DevelopmentAgreement.txt",
        "perturbation": [
            {
                "type": "Structural Flaws - In Text Contradiction",
                "original_text": "10.2.11 Neither Xencor nor its Affiliates or, to the knowledge of Xencor, its licensees, sublicensees or subcontractors have made any material misstatements in any regulatory filing with any Regulatory Authority with respect to the Antibody or Product.\n\n10.2.12 Neither Xencor nor, to the knowledge of Xencor, its Affiliates, licensees, sublicensees or independent contractors have received any notices or claims of noncompliance with Applicable Law relating to activities conducted by or facilities used by, Xencor, its Affiliates, licensees, sublicensees or independent contractors in connection with the Development or Manufacture of Antibody or Product, and Xencor is not aware of any reasonable basis for any such notices or claims.",
                "changed_text": "10.2.11 To Xencor's knowledge, Xencor's Affiliates, licensees, sublicensees or subcontractors may have made material misstatements in regulatory filings with any Regulatory Authority with respect to the Antibody or Product, and Xencor assumes no liability in connection to such misstatements.\n\n10.2.12 To Xencor's knowledge, Xencor's Affiliates, licensees, sublicensees or independent contractors may have received notices or claims of noncompliance with Applicable Law relating to activities conducted by or facilities used by, Xencor, its Affiliates, licensees, sublicensees or independent contractors in connection with the Development or Manufacture of Antibody or Product, and Xencor is aware of a reasonable basis for such notices or claims.",
                "explanation": "The original clauses state that Xencor has not made any material misstatements in any regulatory filings and has not received any notices or claims of noncompliance with Applicable Law. The modified version introduces uncertainty by saying Xencor's Affiliates may have made these misstatements and received noncompliance notices, directly contradicting the original statement and creating uncertainty about Xencor's liability.",
                "location": "Section 10.2.11 and 10.2.12"
            },
            {
                "type": "Structural Flaws - In Text Contradiction",
                "original_text": "2.4 Restrictive Covenants. Aimmune hereby covenants and agrees that it shall not (and shall cause the other Aimmune Agreement Entities not to), either directly or indirectly, Develop, Manufacture, or Commercialize the Product for use outside the Licensed Field.",
                "changed_text": "2.4 Restrictive Covenants. Aimmune may, at its discretion, and shall cause the other Aimmune Agreement Entities to, either directly or indirectly, Develop, Manufacture, or Commercialize the Product for use outside the Licensed Field.",
                "explanation": "The original text included a restrictive covenant that limited Aimmune's use of the product outside of the Licensed Field. The modified text creates contradiction by stating that Aimmune may, at its discretion, Develop, Manufacture or Commercialize the product for use outside of the licensed field.",
                "location": "Section 2.4"
            }
        ]
    }
]